Ex Vivo Selective Depletion of Alloreactive Donor T Lymphocytes Utilizing RFT5-SMPT-dgA, a Specific Anti-Interleukin-2 Receptor Immunotoxin: Reducing Graft-Versus-Host Disease Risk Associated With HLA [human lymphocyte antigen]-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in Older Adults
Phase of Trial: Phase II
Latest Information Update: 19 May 2010
At a glance
- Drugs Monoclonal antibody RFT5-ricin chain A conjugate (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine
- Indications Graft-versus-host disease; Haematological malignancies
- Focus Therapeutic Use
- 22 Oct 2005 New trial record.